Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Aberrant glycosylation is an oncogenesis hallmark
- Cell transformation & glycoconjugate biosynthesis
- Aberrant glycosylation & blood group expression
- Study by Hajime Masamune
- Cancer and healthy cells show difference in lectin
- Cancer glycosignatures in transformed cells
- Human and mouse glycan-related genes
- Small sample of glycosyltransferase reactions
- Alteration of glycan expression
- Understanding altered glycans during oncogenesis
- Glycan changes in breast cancer
- Aberrant N-glycan branching during oncogenesis
- The N-linked glycan synthesized by GnT-V
- L-PHA binding to breast tissue sections
- The signaling pathway of GnT-V expression
- GnT-V up-regulation in cancer tissues
- GnT-V expression levels regulate cell-cell adhesion
- Glycan-driven feedback amplification loop
- GnT-V is a multi-function controller
- GnT-V deletion delayed her-2-induced tumor onset
- GnT-V deletion reduced tumor initiating cells (TIC)
- Identifying potential biomarkers of breast cancer
- Depicting targeted glycoproteomics with L-PHA
- Identification of GnT-V products in tissue extracts
- Tumor-specific glycoproteins bound to L-PHA
- Information on the glycoprotein periostin
- Recent data on periostin and cancer stem cells
- Glycosyltransferase loss in oncogenesis
- Tn and sialyl Tn antigens cell surface expression
- Overview of Tn & STn expression in human cancer
- O-glycan structures
- Biosynthesis of O-glycans
- Cosmc - a specific chaperone of T-synthase
- Dysfunctional Cosmc & Tn and sialyl Tn antigens
- Effects of loss of T-synthase
- Acknowledgements
- References (1)
- References (2)
- References (3)
Topics Covered
- Glycomics
- Tumor-specific glycoproteins
- Aberrant glycosylation
- Understanding altered glycans during oncogenesis
- Glycosyltransferase
- GnT-V in oncogenesis
- L-PHA in cancer
- Tn and sialyl Tn antigens
- O-glycan structures
- Dysfunctional Cosmc
- Loss of T-synthase
- Overexpression of Periostin
Talk Citation
Pierce, M. (2012, November 27). Glycosylation changes during oncogenesis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/PIER7487.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Michael Pierce has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.